Evidence map›Paper›PMID 33203055›Full record

ArticleMolecules (Basel, Switzerland)2020

Pharmacological Characterization of 4-Methylthioamphetamine Derivatives.

Fabrizzio G Guajardo, Victoria B Velásquez, Daniela Raby, Gabriel Núñez-Vivanco, Patricio Iturriaga-Vásquez, Rodrigo A España, Miguel Reyes-Parada, Ramón Sotomayor-Zárate

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Fabrizzio G GuajardoLaboratorio de Neuroquímica y Neurofarmacología, Centro de Neurobiología y Fisiopatología Integrativa (CENFI), Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.
Victoria B VelásquezLaboratorio de Neuroquímica y Neurofarmacología, Centro de Neurobiología y Fisiopatología Integrativa (CENFI), Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.
Daniela RabyLaboratorio de Neuroquímica y Neurofarmacología, Centro de Neurobiología y Fisiopatología Integrativa (CENFI), Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.
Gabriel Núñez-VivancoCenter for Bioinformatics, Simulations and Modelling, University of Talca, Talca 3460000, Chile.
Patricio Iturriaga-VásquezLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.ORCID 0000-0003-0553-1014
Rodrigo A EspañaDepartment of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA 19129, USA.
Miguel Reyes-ParadaCentro de Investigación Biomédica y Aplicada (CIBAP), Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Santiago de Chile, Santiago 9170022, Chile.ORCID 0000-0002-2376-990X
Ramón Sotomayor-ZárateLaboratorio de Neuroquímica y Neurofarmacología, Centro de Neurobiología y Fisiopatología Integrativa (CENFI), Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.ORCID 0000-0002-1239-5367
University of Valparaíso · CLDrexel University · USUniversidad de La Frontera · CLUniversidad de Santiago de Chile · CLUniversity of Talca · CL

Funding

DIUV-CI 01/2006Fondo Nacional de Desarrollo Científico y Tecnológico 117-0662Fondo Nacional de Desarrollo Científico y Tecnológico 120-0474NIH HHS DA031900NIH HHS DA043787
6 · The paper itself

Abstract

Amphetamine derivatives have been used in a wide variety of pathologies because of their pharmacological properties as psychostimulants, entactogens, anorectics, and antidepressants. However, adverse cardiovascular effects (sympathomimetics) and substance abuse problems (psychotropic and hallucinogenic effects) have limited their use. 4-Methylthioamphetamine (MTA) is an amphetamine derivative that has shown to inhibit monoamine uptake and monoamine oxidase. However, the pharmacological characterization (neurochemical, behavioral, and safety) of its derivatives 4-ethylthioamphetamine (ETA) and 4-methylthio-phenil-2-butanamine (MT-But) have not been studied. In the current experiments, we show that ETA and MT-But do not increase locomotor activity and conditioned place preference with respect to MTA. At the neurochemical level, ETA and MT-But do not increase in vivo DA release in striatum, but ETA and MT-But affect the nucleus accumbens bioaccumulation of DA and DOPAC. Regarding cardiovascular effects, the administration of MTA and ETA increased the mean arterial pressure and only ETA significantly increases the heart rate. Our results show that the pharmacological and safety profiles of MTA are modulated by changing the methyl-thio group or the methyl group of the aminoethyl chain.

Indexed as

3,4-Dihydroxyphenylacetic AcidAmphetamineAmphetaminesAnimalsBehavior, AnimalBody TemperatureCorpus StriatumDopamineLigandsLocomotionMaleMolecular Docking SimulationNucleus AccumbensOxygenRatsRats, Sprague-Dawley3,4-Dihydroxyphenylacetic Acid4-methylthioamphetamineAmphetamineAmphetaminesDopamineLigandsOxygenSerotonin Plasma Membrane Transport Proteinsconditioned place preference (CPP)DATFSCVlocomotor activitymolecular dockingreward

Identifiers

PMID33203055
PMCPMC7696343
OpenAlexW3103126642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.